TP53 and acute myeloid leukemia: AML cells often develop multidrug resistance (MDR) through mechanisms such as the overexpression of efflux pumps (e.g., ATP-binding cassette transporters) and TP53 mutations [15, 16], leading to limited therapeutic options and treatment failure.